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hyperphosphataemia, Nutr Metab CaAbstract Background and Aim: Elevated serum phosphate and calciumephosphate levels
play an important role in the pathogenesis of vascular calcifications in uraemic patients and
appear to be associated with increased cardiovascular mortality. We aimed to evaluate the
effects of a partial replacement of food protein with a low-phosphorus and low-potassium
whey protein concentrate on phosphate levels of dialysis patients with hyperphosphataemia.
Methods and Results: Twenty-seven patients undergoing chronic haemodialysis were studied
for a 3-month period. In the intervention group (n Z 15), food protein were replaced by 30
or 40 g of low-phosphorus and low-potassium protein concentrate aimed at limiting the phos-
phate intake. In the control group (nZ 12) no changes were made to their usual diet. Anthro-
pometric measurements, biochemical markers and dietary interviews were registered at
baseline and during the follow-up period. From baseline to the end of the study, in the inter-
vention group, serum phosphate and circulating intact parathyroid hormone levels lessened
significantly (8.3  1.2 mg/dL vs 5.7  1.4 mg/dL and 488  205 pg/ml vs 177  100 pg/ml
respectively; p < 0.05) with decreasing of phosphate and potassium intake. No significant
differences were found in the control group. No significant changes were observed in serum
albumin, calcium, potassium, Kt/V, body weight and body composition in both the intervention
and control groups.
Conclusion: Dietary intake of phosphate mainly comes from protein sources, so dietary phos-
phorus restriction may lead to a protein/energy malnutrition in a dialysis patient. A phosphorus-
controlled diet plan including a nutritional substitute resulted in serumphosphate and intact para-
thyroid hormone decrease without nutritional status modifications in dialysis patients.
ª 2010 Elsevier B.V. All rights reserved.1 7463216; fax: þ39 081 7463639.
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Table 1 Nutritional composition of the low-phosphorus
and low-potassium whey protein concentrate (Prother).
100 g
Energy kcal (kJ) 369 (1550)
Protein g 89.0
Carbohydrate g 1.0
Fat g 0.8
Phosphorus g 0.21
Calcium g 0.6
Sodium g 0.25
Potassium g 0.4
Iron mg 9.3
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+ MODELControlling hyperphosphataemia is crucial to prevent the
development of a secondary hyperparathyroidism and renal
osteodystrophy in chronic kidney disease patients. In addi-
tion, hyperphosphataemia, causing soft-tissue calcifica-
tions, is emerging as an independent risk factor of
cardiovascular mortality in dialysis patients [1e3]. However,
a positive phosphate balance frequently occurs in conven-
tional dialysis patients. High dietary phosphate intake
(>1200 mg/day) is the most significant contributor to high
serum phosphate levels [4]. Because of standard haemo-
dialysis removing w900 mg of phosphate three times per
week, more than 90% of patients with uraemia require
phosphate binders to avoid hyperphosphataemia [5].
Therefore, both the use of phosphate binders and the limi-
tation of phosphate dietary intake may represent the main
approaches for good phosphate control in dialysis patients
[6]. A restricted dietary intake should be the most effective
method to prevent this condition. However, dietary phos-
phate is strictly related to dietary protein content [7] and the
conflict between adequate protein and phosphate intake is
a well-known problem in the clinical practice [8]. A highly
significant correlation between dietary phosphate and
protein intake has been demonstrated [9]. For an optimal
daily protein intake (1e1.2 g/kg/day), the phosphate intake
is 778e1444 mg d1; therefore, because of protein contrib-
uting to a significant percentage of the total dietary phos-
phate intake, dialysis patients need to markedly limit their
protein intake. To achieve the least phosphate intakewith an
adequate protein intake, an accurate selection of foods is
needed. A diet including foods with a low phosphate content
per gram of protein should be followed [4]. Despite the die-
tary phosphate restriction and the use of phosphate binders,
serum phosphate levels remain significantly high in approx-
imately 65% of the dialysis population [10].
The purpose of the present study was to evaluate the
effects of a partial replacement of food protein with
a low-phosphorus and low-potassium whey protein
concentrate on phosphate levels of dialysis patients with
hyperphosphataemia.Table 2 Baseline characteristics in the intervention and
control groups.
Intervention Control
Number 15 12
M/F 8/7 7/5
Age (years) 50.2  9.0 48.7  9.7
Dialysis age (months) 20.3  19.5 19.7  16.3
Body weight (kg) 69.9  13.6 70.2  8.4
Height (cm) 160.3  9.1 162.1  9.7
Body Mass Index (kg/m2) 27.2  6.4 27.0  5.3
Phosphate (mg/dl) 8.1  0.9 8.2  0.7
Sevelamer use (n [%]) 8 (53) 6 (50)
Aluminium hydroxide
use (n [%])
3 (20) 3 (25)
Lanthanum use (n [%]) 2 (13) 1 (8)
Calcium carbonate use (n [%]) 1 (7) 1 (8)
Multiple binders use (n [%]) 1 (7) 1 (8)
Active vitamin D derivative
use (n [%])
7 (47) 6 (50)Methods
This study was performed on 27 chronic haemodialysis
patients (15 male and 12 female, mean age 50.2 9.0 years)
for a 3-month period. Inclusion criteria were haemodialysis
treatment for at least 6 months; no allergy to cow’s milk
protein and hyperphosphataemia (serum phosphate
6.5 mg/dl) with stable dialysis dose and modality, dietary
intakes, body weight and biochemical markers for at least 3
months. All patients were on thrice weekly 4 h standard
bicarbonate haemodialysis, and were clinically stable and
without other illness. Subjects with diabetes, liver disease,
malignancy, parathyroidectomy or psychiatric disease and
those who were non-collaborative were excluded. Most
patients received both phosphate binders (sevelamer,
lanthanum carbonate, calcium carbonate and aluminium
hydroxide) and vitaminDanalogues. No patient hadanabolic
steroids or different protein supplements. No changes in
dialysis prescription, medications or body weight were
mandated. Eating habits, energy and protein intake were
estimated in all patients. As the compliance to dietaryPlease cite this article in press as: Guida B, et al., Dietary phosphate re
hyperphosphataemia, Nutr Metab Cardiovasc Dis (2010), doi:10.1016/restrictions on high-phosphate foods is sometimes difficult,
patients were asked not to change their eating habits and
they were instructed to keep unchanged their total protein
and energy intake throughout the study. No patient, initially
assessed for inclusion into the study, refused to enter the
study. Patients were randomly assigned to either maintain
their usual diet (control group, nZ 12) or partially replace
dietary protein intake with a low-phosphorus and low-
potassium whey protein concentrate (intervention group,
n Z 15) for a 3-month period. Patients in the intervention
group were instructed to consume 30 or 40 g of the low-
phosphorus and low-potassium protein concentrate
powder (PROther, DMF Dietetic Metabolic Food) (Table 1)
dissolved in 150e200 mL of water or some other liquid in
place of usual daily portion sizes of protein-rich foods
includingmilk consumed at breakfast andmeat, fish, eggs or
dairy and poultry products consumed at lunch time. They
were supplied with adequate amounts of sugar and/or oil,
depending on usual energy intake. Dietary adherence was
monitored monthly in all patients. Compliance with the diet
was ascertained through interviews conducted by an expert
dietician using a detailed food-frequency questionnaire
including 130 foods and beverages [11]. All patients
continued to consume their phosphate binders.striction in dialysis patients: A new approach for the treatment of
j.numecd.2010.02.021
Figure 1 Serum phosphate and calcium levels before the trial (T-30), at baseline (T0) and after 1, 2 and 3 months (T30, T60 and
T90, respectively) and serum parathormone (PTH) levels at baseline and after 3 months, in Intervention (black) and Control (gray)
groups. *p Z 0.000 vs T-30 and baseline (ANOVA with a Bonferroni post hoc test), **p < 0.001 vs baseline (Student’s paired test).
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+ MODELBlood samples were drawn before the dialysis session of
the patients to measure serum calcium, phosphate,
albumin (Behring Nephelometer, Dade Behring Inc, Newark,
DE), creatinine, intact parathyroid hormone (iPTH) and the
plasma levels of urea (reported as blood urea nitrogen,
BUN). A sample was also obtained at the end of the dialysis
session to measure the BUN value. The Kt/V, which is
a measure of the dialysis dose, was calculated by the
following equation: In (R  0.008  Td ) þ (4  3.5R) UF/
W, where: R Z BUN post-HD/BUN pre-HD, Td Z HD time
(hours), UF Z ultrafiltration volume, W Z body weight at
end of dialysis session (kg). Kt/V is a dimensionless measure
of dialytic dose, where K is the urea dialytic clearance
(expressed in ml/ml), t is treatment time (in minutes) and V
is the body volume cleared by urea at a rate K (V approxi-
mately equals total body water, that is, 58% of dry weight)
[12]. iPTH was measured by immunoradiometric assay
(IRMA, Scantibodies Laboratory Inc., Santee, CA; normal
range, 10 to 65 pg/mL).
Anthropometric measurements and biochemical nutri-
tional markers were registered before the trial, at baseline
and after 1, 2 and 3 months. Body weight was always
measured at the end of the of haemodialysis session. Body
mass index (BMI) was calculated as the ratio body weight/
height2 (kg/m2) [13]; body composition was qualitatively
evaluated according to the patterns of bioelectricalPlease cite this article in press as: Guida B, et al., Dietary phosphate re
hyperphosphataemia, Nutr Metab Cardiovasc Dis (2010), doi:10.1016/impedance vector analysis [14]; resistance (Rs) and reac-
tance (Xc) were directly measured in ohms (U) at 50 kHz
using the bioelectrical impedance analyser (BIA 101 RJL,
Akern Bioresearch, Firenze, Italy) according to the standard
tetrapolar technique [15,16]. Measurements were carried
in standardised conditions 30 min after the end of the
dialysis session. Rs and Xc measurements were normalised
by the stature of the patient and plotted as point vector on
the gender-specific 50th, 75th and 95th tolerance ellipses
calculated from the reference healthy population [14]. The
vector’s length (Z ) indicates the changes in tissue hydra-
tion and was calculated as jZjZ O[(R/H )2 þ (Xc/H )2]. The
phase angle has been found to be a sensitive indicator of
malnutrition depending on body cell mass changes and was
calculated as the arctan (Xc/R) in degrees. The same
investigators performed anthropometry and bioelectrical
impedance (BIA) measurements.
The study was approved by the Ethical Committee of the
Medical School of the University Federico II of Naples and
all subjects gave their informed consent.Statistics
Values are given as mean  standard deviation. The inde-
pendent Student’s t-test was used to compare differencesstriction in dialysis patients: A new approach for the treatment of
j.numecd.2010.02.021
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hyperphosphataemia, Nutr Metab Cardiovasc Dis (2010), doi:10.ate re
1016/between control and intervention groups at baseline and
the paired Student’s t-test was used to analyse the differ-
ence from baseline to the end of the study. Analysis of
variance (ANOVA) for repeated measurements and the
Bonferroni post hoc test were used for comparison of the
dependent variables in the different time periods. P < 0.05
was considered statistically significant.
Results
Baseline data are shown in Table 2. Demographic and
anthropometric data, mean serum phosphate and iPTH
levels, concomitant vitamin D and the use of phosphate
binders gave similar results between intervention and control
groups. All patients completed the study and no patient dis-
continued the treatment prematurely. At the end of follow-
up, patients of the intervention group showed a significant
decrease in mean serum phosphate and iPTH levels
(8.3  1.2 mg/dL vs 5.7  1.4 mg/dL, p Z 0.000, and
488 205 pg/ml vs 177 100 pg/ml,p< 0.001, respectively),
while no significant changes were found in the control group.
No significant changes in serumalbumin, calcium, potassium,
Kt/Vandbodyweightwere observed inboth, the intervention
and control groups (Fig. 1 and Table 3). Interdialytic weight
gain and pre-dialytic blood pressure did not change signifi-
cantly in both intervention and control groups. Moreover, our
findings show that no statistically significant differenceswere
observed in Rs, Xc, phase angle and in the vector length
measures, as assessedby BIA between baseline and theendof
the study in both groups (Table 4).
At the end of follow-up, patients of the intervention group
showed a significant decrease in phosphate (37% vs. base-
line, p < 0.05) and potassium (23% vs. baseline, p < 0.05)
intake, whereas no significant differences were observed for
energy and protein intake. A decrease of the dietary phos-
phateeprotein ratio (37% vs. baseline, p < 0.05) also
occurred. In the control group, conversely, no significant
differences in phosphate, potassium, energy and protein
intake were observed at the end of the study (Table 4).
Discussion
In a recently published study of 40,538 haemodialysis
patients, higher serum phosphate levels were consistently
associated with increased death risks [2]. Similarly, a rise in
serum phosphate over time is associated with increasing
mortality [3].
Dietary restrictions to control serum phosphate are
recommended in dialysis patients and are usually associ-
ated with a reduction in protein intake, as phosphate and
protein intakes are related. This may lead to malnutrition
and poor survival in the patients [17,18]. Therefore, dietary
phosphate restriction should always be considered accord-
ing to an adequate protein intake of >1 g/kg/day. Without
any phosphate binders, an average of 60e80% of the
phosphate intake is absorbed in the gut [19]. If binders are
employed, the phosphate absorbed could be reduced to
40% [20e23]; in these circumstances, 642 mg of phosphate
is absorbed and this value should be a critical amount.
The present study shows that a partial replacement of
natural foods, which are naturally high in phosphate, withstriction in dialysis patients: A new approach for the treatment of
j.numecd.2010.02.021
Table 4 Bioelectrical impedance data and mean dietary intakes in Intervention and Control groups at baseline (T0) and after 3
months (T90).
Intervention group n Z 15 Control group n Z 12
T0 T90 p value T0 T90 p value
Resistence (Ohm) 527  88 509  90 0.58 530  68 515  8 0.64
Reactance (Ohm) 62  15 58  15 0.47 57  12 59  16 0.73
Phase Angle () 6.8  1.7 6.4  1.2 0.46 6.7  1.9 6.9  1.3 0.76
Vector length (Ohm/m) 332  64 320  63 0.60 330  59 350  60 0.42
Energy intake (kcal/kga) 39.2  8.5 (36.7  9.3) þ (2.2  0.3)b 0.92 39.9  7.2 39.7  10.2 0.96
Protein intake (g/kga) 1.3  0.2 (0.8  0.1) þ (0.5  0.1)b 1.00 1.3  0.5 1.3  0.3 1.00
Phosphate intake (mg/day) 1070.0  143.6 672.3  119.8 0.000 1100.3  115.6 1098.7  119.7 0.97
Potassium intake (mg/day) 1675.4  363.6 1291.8  278.0 0.000 1695.4  333.8 1705.0  293.3 0.91
Phosphorus/protein intake 11.6  3.1 7.3  1.5 0.000 12.0  3.5 11.9  2.7 0.94
a kg of ideal body weight.
b From protein concentrate (PROther).
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+ MODELa low-phosphorus protein concentrate, does affect serum
phosphate levels in dialysis patients with hyper-
phosphataemia (Fig. 1). Our data are in keeping with the
chance to reduce dietary phosphate content without change
in protein intake, limiting the phosphate load. In addition,
natural foods, such as uncooked meat and poultry, may
contain additives that increase phosphorus and potassium
content by as much as almost two- and threefold, respec-
tively [24]. Educating patients to avoid processed and fast
foods prepared with phosphorus-containing additives results
in clinically significant improvements in serum phosphate
levels [25]. Therefore, even though food additives are
another significant source of phosphate, this study was
focussed on examining the contribution of phosphate that is
naturally present in food on serum phosphate levels.
In dialysis patients, a neutral phosphate balance could
be reached only by a marked dietary protein restriction [7]
that may induce malnutrition [17,18]. However, although
a significant decrease of dietary phosphate intake was
obtained in the intervention group, no modification of total
energy and protein intake was observed. A quite low
phosphate-to-protein ratio in all patients at baseline is due
to general dietary recommendations by nephrologists in an
attempt to reduce phosphorus intake; however, a signifi-
cant decrease of the dietary phosphateeprotein ratio
occurred only in the intervention group. Nutritional status
was also maintained unchanged during the study period, as
demonstrated by the constancy of both body weight and
biochemical markers (Table 4). In addition, no modification
in body composition was observed, as assessed by BIA. In
fact, either phase angle (representative of body cell mass)
or vector length (representative of hydration status)
remained unchanged after 3 months of follow-up in the
intervention group (Table 4). These findings also support
the safety of this diet.
‘Moreover, phosphate retention is a main factor in the
development of secondary hyperparathyroidism [20,26].
The increase in iPTH levels causes osteitis fibrosa, which
in the past was the most frequent form of bone disease
observed in the dialysis population. Serum iPTH levels
significantly decreased in the intervention group at the
end of the 3-month study period. In contrast, no signifi-
cant difference was observed in the control groupPlease cite this article in press as: Guida B, et al., Dietary phosphate re
hyperphosphataemia, Nutr Metab Cardiovasc Dis (2010), doi:10.1016/(Fig. 1). This result suggests that a controlled serum
phosphate concentration could be partially responsible
for lowering iPTH levels already after a 3-month period in
dialysis patients. Nevertheless, this important finding
must be cautiously interpreted because of the small
simple size.
Furthermore, patients showed good diet compliance
because they found the nutritional substitute in their diet
quite satisfactory. None of the treated patients dropped
out of the study. This low-phosphorus and low-potassium
protein concentrate may help patients maintain normal
serum potassium levels as well; this is very important for
low mortality in haemodialysis patients [27].
The major limitation of this study is the small sample
size that decreased the statistical power of statistical tests.
Moreover, the estimates obtained from this study can be
used while designing future studies.
In conclusion, this study indicates that innovative
strategies in addition to both traditional dietary and phar-
macological therapy may be useful in hyperphosphataemia
management in dialysis patients. This plan could also lead
to a reduction in the needed dosage of phosphate binders,
ameliorating their compliance and tolerability. We believe
that a phosphate-controlled diet is a very important ther-
apeutic approach to hyperphosphataemia in compliant and
motivated dialysis patients, and the nutritional substitute is
a valid integrated method to achieve it.
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